This meta- analysis demonstrated that resveratrol supplementation among patients with MetS and related disorders  significantly reduced total cholesterol and increased GGT concentrations , but did not affect triglycerides , LDL- , HDL-cholesterol , ALT , and AST concentrations .
This data suggests that resveratrol may have a potential cardio-protective effect in patients with MetS and related disorders
There are current trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes among patients with metabolic syndrome ( MetS ) and related disorders ; however , their findings are controversial .
This systematic review and meta- analysis were aim ed to determine the effects of resveratrol supplementation on lipid profiles and liver enzymes among patients with MetS and related disorders .
Efficacy of an orlistat-resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial.
OBJECTIVE To evaluate the efficacy of an orlistat-resveratrol ( O-R ) combination in subjects with obesity over a 6-month period . METHODS This study was a double-blind , parallel , r and omized controlled clinical trial . Patients fulfilling the selection criteria ( age from 20 to 60 years and body mass index ( BMI ) ≥30 and ≤39.9 kg/m(2 ) ) consumed an energy-reduced diet with 500 fewer calories than their usual diet for 2 weeks . Then the participants were r and omly assigned to four groups , placebo , resveratrol , orlistat , or O-R , and they consumed the energy-reduced diet for 6 months . The study consisted of seven visits . During each visit , a 24-h recall was performed , along with measurements of anthropometric and serum biochemical parameters . RESULTS A total of 161 participants were selected . Of these , 84 participants completed the study . A significant weight loss of -6.82 kg ( 95 % CI -8.37 to -5.26 ) was observed in the O-R group compared with -3.50 kg ( -5.05 to -1.95 , P = 0.021 ) in the placebo group . In contrast , the -6.02 kg ( -7.68 to -4.36 ) orlistat and -4.68 kg ( -6.64 to -2.71 ) resveratrol monotherapy losses did not significantly differ from the placebo . Significant decreases in BMI , waist circumference , fat mass , triglycerides , leptin , and leptin/adiponectin ratio were observed with the O-R combination . CONCLUSIONS The O-R combination was the most effective weight loss treatment
This meta- analysis demonstrated that resveratrol supplementation among patients with MetS and related disorders  significantly reduced total cholesterol and increased GGT concentrations , but did not affect triglycerides , LDL- , HDL-cholesterol , ALT , and AST concentrations .
This data suggests that resveratrol may have a potential cardio-protective effect in patients with MetS and related disorders
There are current trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes among patients with metabolic syndrome ( MetS ) and related disorders ; however , their findings are controversial .
This systematic review and meta- analysis were aim ed to determine the effects of resveratrol supplementation on lipid profiles and liver enzymes among patients with MetS and related disorders .